AstraZeneca将直接列在NYSE上,以11月3日的股东表决取代ADRs。 AstraZeneca to list directly on NYSE, replacing ADRs, with shareholder vote set for Nov. 3.

AstraZeneca计划直接列出其在纽约证券交易所的普通股份,取代其目前的美国存款收据,以改善全球投资者的准入,同时保持其联合王国总部和在伦敦证券交易所的主要上市地位。 AstraZeneca plans to directly list its ordinary shares on the New York Stock Exchange, replacing its current American Depositary Receipts, to improve global investor access while keeping its UK headquarters and primary listing on the London Stock Exchange. 这一举动是加强美国存在的更广泛战略的一部分,它创造了42%的销售额,雇用了18 000多人,同时在美国研究、开发和细胞疗法制造方面投资500亿美元。 The move, part of a broader strategy to strengthen its U.S. presence—where it generates 42% of sales and employs over 18,000 people—comes alongside a $50 billion investment in U.S. research, development, and cell therapy manufacturing. 这项改变需要股东在11月3日的会议上批准。 The change requires shareholder approval at a meeting on November 3.